World Lifestyler
  • Art & Culture
    • Books & Literature
    • Cinema & Film
    • Design & Architecture
    • Exhibitions
    • Theatre
    • Music
  • Lifestyle
    • Fashion
    • Health & Fitness
    • Home & Living
    • Luxury Living
    • Car Reviews
    • Collectors
    • Luxury Cars
    • Planes
    • Private Jets
    • Yachts
  • Travel
    • Exclusives
    • Fashion Events
    • Festivals
    • Meetups
    • Outdoor Excursions
    • Road Trips
    • VIP Experiences
  • Food & Drink
    • Beers & Spirits
    • Chefs & Cooks
    • City Eating Guides
    • Fine Dining
    • Recipes
    • Restaurant Reviews
  • Adventure & Tours
  • City Guides
  • Cruises
  • Resorts & Spas
  • Reviews & Tips
  • Art & Culture
    • Books & Literature
    • Cinema & Film
    • Design & Architecture
    • Exhibitions
    • Theatre
    • Music
  • Lifestyle
    • Fashion
    • Health & Fitness
    • Home & Living
    • Luxury Living
    • Car Reviews
    • Collectors
    • Luxury Cars
    • Planes
    • Private Jets
    • Yachts
  • Travel
    • Exclusives
    • Fashion Events
    • Festivals
    • Meetups
    • Outdoor Excursions
    • Road Trips
    • VIP Experiences
  • Food & Drink
    • Beers & Spirits
    • Chefs & Cooks
    • City Eating Guides
    • Fine Dining
    • Recipes
    • Restaurant Reviews
  • Adventure & Tours
  • City Guides
  • Cruises
  • Resorts & Spas
  • Reviews & Tips
No Result
View All Result
World Lifestyler
No Result
View All Result
Home Lifestyle Health & Fitness

bitBiome and Kyoritsu Seiyaku Announce Strategic Collaboration in Animal Health and Nutrition

Cision PR Newswire by Cision PR Newswire
March 9, 2026
in Health & Fitness
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

TOKYO, March 9, 2026 /PRNewswire/ — bitBiome, Inc., a pioneer in the discovery, design, and engineering of novel bio-manufactured products, today announced a joint development and collaboration agreement with Kyoritsu Seiyaku Corporation, a leading animal health company in Japan.


bitBiome logo (PRNewsfoto/bitBiome)

Under this collaboration, bitBiome and Kyoritsu Seiyaku will co-develop products utilizing advanced biotechnology for applications in animal health and nutrition. bitBiome will lead the development of products and manufacturing processes, while working to commercialize and promote these technologies and products in the global market.

bitBiome has developed a unique technology platform that integrates the world’s largest microbial sequence database with cutting-edge enzyme technology, proprietary strain engineering, and scaled-up biomanufacturing process development capabilities. This platform enables efficient access to novel and affordable biological solutions. By combining these capabilities with Kyoritsu Seiyaku’s long-standing commitment to veterinary medicine, this partnership is positioned to deliver differentiated biological solutions to the market.

“This collaboration reflects our belief that bio-based products play a critical role in building a more sustainable global economy,” said Yuji Suzuki, CEO of bitBiome. “By combining our discovery and development capabilities with Kyoritsu Seiyaku’s deep expertise in animal health, we will contribute to improving the quality of health management and care for livestock and pets worldwide through innovative technologies and products.”

Kyoritsu Seiyaku has supported the health of pets and livestock in Japan and overseas markets based on decades of experience and expertise in veterinary medicine. Through this collaboration, the company aims to translate advanced biotechnology into practical solutions and promote a strategic partnership focused on solving global challenges, such as the realization of a sustainable society.

About Kyoritsu Seiyaku Corporation

Founded in 1955. With a mission to “Create the path for animals and people to move forward together,” the company is a leader in animal health, involved in the development, manufacture, sale, import, and export of pharmaceuticals for dogs, cats, and livestock.

  • Name: Kyoritsu Seiyaku Corporation
  • Representative: Takaaki Takai, President & CEO
  • Established: May 1955
  • Capital: 55 million JPY
  • Employees: 728 (as of the end of May 2025)
  • Business: Development, manufacture, sale, import, and export of veterinary pharmaceuticals, etc.
  • URL: https://www.kyoritsuseiyaku.co.jp/

About bitBiome

bitBiome is a biotechnology company unlocking the full potential of our planet’s microbes to power the future of the bioeconomy. bitBiome’s platform is built on their proprietary single-cell microbial genome analysis technology, bit-MAP®, which has enabled the creation of bit-GEM: an extensive and groundbreakingly diverse and growing microbial database of over 2.5 billion sequences, predominantly containing sequences not present in public databases. Leveraging their expertise in bioinformatics, machine learning and dominant use of AI technologies, the company practices a comprehensive enzyme discovery and enzyme, pathway and proprietary strain engineering platform, bit-QED, to rapidly develop and affordably manufacture bio-based products. bitBiome is committed to improving existing biomanufacturing industries and creating new ones by delivering unique nature-inspired bio-based products that cannot be enabled elsewhere.

To learn more about bitBiome’s platform and services, visit www.bitbiome.bio.

Contact: info@bitbiome.bio


Kyoritsu Seiyaku Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bitbiome-and-kyoritsu-seiyaku-announce-strategic-collaboration-in-animal-health-and-nutrition-302708299.html

SOURCE bitBiome

Cision PR Newswire

Cision PR Newswire

Related Posts

Residential Home Health Expands Eastern Pennsylvania Footprint with Acquisition of Covenant Home Health

March 9, 2026

In HelloNation, Cannabis Expert Shellie Grammer of Roseburg Clarifies THC vs. CBD Effects

March 9, 2026

MWW Health Launches HealthPulse, an AI-Powered Policy Intelligence and Communications Solution for Healthcare Leaders

March 9, 2026

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

March 9, 2026

Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 MDA Clinical & Scientific Conference

March 9, 2026

Healogics Appoints John P. Landino as Chief Development Officer

March 9, 2026

Popular News

  • W.T.B. Financial Corporation Announces Share Repurchase Authorization

    0 shares
    Share 0 Tweet 0
  • Debevoise Announces New Leadership Structure Across Global Finance Practice and Addition of Leveraged Finance Partner Mayer Steinman

    0 shares
    Share 0 Tweet 0
  • Kimbell Royalty Partners Announces $100 Million Common Unit Repurchase Program

    0 shares
    Share 0 Tweet 0
  • NAPCO Security Technologies Selected for Inclusion in the S&P SmallCap 600 Index

    0 shares
    Share 0 Tweet 0
  • Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for February 2026

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler